Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

In TALAPRO-3, adding talazoparib to ADT plus enzalutamide in de novo metastatic hormone-sensitive prostate cancer with DNA repair alterations sharply improved radiographic progression-free survival. Fizazi says the benefit appears across alterations, including BRCA2 and biallelic CDK12, though gene-by-gene homework remains. He also sees an overall survival signal, but final analysis is pending.

Related Insights

In prostate cancer, the benefit of PARP inhibitors is overwhelmingly driven by BRCA2 mutations, which are more common than BRCA1. While PALB2 also shows a strong response, genes like BRCA1 offer only modest benefit, and ATM mutations show almost no response. This highlights the need for a gene-specific, not class-specific, approach to treatment.

In prostate cancer, BRCA2 mutations typically involve complete gene loss, making them a significant oncogenic event. In contrast, BRCA1 mutations are often "passenger" mutations without complete loss of function, leading to reduced benefit from PARP inhibitors. This differs from breast and ovarian cancers, where both are highly significant.

When a patient has a BRCA2 mutation, clinicians on the panel view it as such a dominant predictive biomarker that they would prioritize a PARP inhibitor-based triplet regimen. This single genetic finding often outweighs other clinical factors or even the potential addition of docetaxel in treatment decisions.

Though cross-trial comparisons are imperfect, Grade 3+ anemia rates offer a stark contrast between approved PARP+ARPI combinations. The rate was 16% for olaparib+abiraterone (PROPEL) versus a much higher 49% for talazoparib+enzalutamide (TALAPRO-2). This suggests toxicity profiles should be a key factor in treatment selection.

Not all DNA damage repair gene alterations create PARP inhibitor sensitivity. Clinical data from multiple trials (TRITON, PROfound, TALAPRO-2) consistently shows that while BRCA1/2 mutations confer significant benefit, alterations in genes like ATM and CHEK2, which are not core to homologous recombination repair (HRR), do not.

Unlike a competing trial's marginal benefit (HR 0.8) for non-BRCA HRR patients, TALAPRO-3 demonstrated a clinically meaningful hazard ratio of 0.56. This superior performance could lead clinicians to strongly favor the talazoparib combination for this specific and often debated patient population.

While benefit from PARP inhibition is typically confined to core HRR genes like BRCA, the TALAPRO-2 study revealed a distinct signal for patients with CDK12 mutations. This non-canonical finding suggests a different mechanism of sensitivity and identifies a new, albeit small, patient population that may benefit from a talazoparib-enzalutamide combination.

Three 2025 trials (AMPLITUDE, PSMA-addition, CAPItello) introduced personalized therapy for metastatic hormone-sensitive prostate cancer. However, significant benefits were confined to narrow subgroups, like BRCA-mutated patients. This suggests future success depends on even more stringent patient selection, not broader application of targeted agents.

For a newly diagnosed metastatic prostate cancer patient, an effective strategy is to initiate ADT alone while immediately ordering NGS testing. Waiting a few weeks for the genetic results before adding an ARPI allows for a more informed treatment choice, such as selecting a PARP inhibitor combination for a patient with a BRCA2 mutation.

A unique three-arm trial allowing crossover between single-agent PARP inhibitors, AR inhibitors, and a combination showed superior outcomes for the upfront combination. This suggests that "saving" a therapy for later is a suboptimal strategy for this biomarker-selected patient population.